Skip to main content

Loading market data...

MLTX

MoonLake Immunotherapeutics

NASDAQ • United states

$10.65

+$0.33

(+3.20%)

Source: Yahoo Finance · Quote time Oct 21, 2026 20:00 GMT+0000

Catalyst Evidence

No verified catalyst stored yet

Click “View” to see the stored chain of evidence (if available).

Management
Credibility
Score

MoonLake Immunotherapeutics (MLTX)

Unavailable

Quotes may be delayed

$906.39M

Market Cap

1,163,561

Volume

Unavailable

P/E Ratio

Unavailable

Div Yield

MoonLake Immunotherapeutics Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: DORFSTRASSE 29, ZUG, V8
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

30 Sep 2026

MoonLake Immunotherapeutics reported Another company event

MoonLake Immunotherapeutics filed an 8-K covering another company event.

14 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in MoonLake Immunotherapeutics.

14 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in MoonLake Immunotherapeutics.

14 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in MoonLake Immunotherapeutics.

10 Aug 2026

MoonLake Immunotherapeutics securities registration filing

MoonLake Immunotherapeutics filed a registration or prospectus document concerning securities.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$477.91M

Total assets (USD)$573.95M

Total liabilities (USD)$145.75M

Shareholders' equity (USD)$428.20M

Long-term debt (USD)$99.51M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Verified Financial Statements Unavailable

Verified financial statement data is not ingested for this stock yet.

Analyst Consensus

Buy

Target: $33.00

209.9% upside potential

📈

Strong Buy

Unavailable

👍

Buy

7

⏸️

Hold

1

📉

Sell

0

8 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 21 Oct 2026, 21:49 UTC Targets range 17.00–50.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

27

Jul 2026

Reich Kristian

Chief Scientific Officer

Open-market sale

$20.00 per share

1,100 shares

22

Jul 2026

Reich Kristian

Chief Scientific Officer

Open-market sale

$20.00 per share

2,448 shares

21

Jul 2026

Reich Kristian

Chief Scientific Officer

Open-market sale

$20.02 per share

50,000 shares

20

Jul 2026

Reich Kristian

Chief Scientific Officer

Open-market sale

$20.09 per share

43,700 shares

15

Jul 2026

Reich Kristian

Chief Scientific Officer

Open-market sale

$20.01 per share

16,105 shares

10

Jul 2026

Santos da Silva Jorge

Director, Chief Executive Officer

Open-market sale

$20.02 per share

68,289 shares

9

Jul 2026

Santos da Silva Jorge

Director, Chief Executive Officer

Open-market sale

$20.01 per share

33,936 shares

1

Jul 2026

Santos da Silva Jorge

Director, Chief Executive Officer

Open-market sale

$20.03 per share

47,775 shares

22

Jun 2026

Bodenstedt Matthias

Chief Financial Officer

Open-market sale

$22.04 per share

39,120 shares

Top Shareholders

Bvf Inc/Il

16,001,284 shares

0% change

6/30/2026

Deep Track Capital, Lp

6,999,025 shares

9.209% change

6/30/2026

T. Rowe Price Investment Management, Inc.

4,280,624 shares

New% change

6/30/2026

Janus Henderson Group Ltd.

3,451,628 shares

64.678% change

3/31/2026

D. E. Shaw & Co., Inc.

3,365,507 shares

40.777% change

6/30/2026

Cormorant Asset Management, Lp

3,205,433 shares

-28.457% change

6/30/2026

Jupiter Topco Llc

3,085,906 shares

New% change

6/30/2026

Logos Global Management Lp

2,675,000 shares

78.333% change

6/30/2026

Weiss Asset Management Lp

2,581,813 shares

51.131% change

6/30/2026

Citadel Advisors Llc

1,972,893 shares

49.041% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 21 Oct 2026, 21:49 UTC· 8 hours ago

Research coverage and investment tools

MoonLake Immunotherapeutics (MLTX) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Pharmaceutical Preparations). Its last price was US$10.65 on 21 Oct 2026. That is 12% of the way from its 52-week low of US$8.90 to its 52-week high of US$23.29. Its market capitalisation was US$906.39 million at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter ended	Reported	EPS	Consensus	Surprise
Jun 2026	8/10/2026	−$0.84	−$0.90	+6.7%
Mar 2026	5/11/2026	−$0.98	−$0.91	-7.7%
Dec 2025	2/25/2026	−$0.92	−$0.92	0.0%
Sep 2025	11/5/2025	−$1.10	−$0.89	-23.6%

Cash and equivalents: $477.91M
Total assets: $573.95M
Total liabilities: $145.75M
Shareholders' equity: $428.20M
Long-term debt: $99.51M

8-K · 30 Sep 2026

MoonLake Immunotherapeutics reported Another company event (opens in a new tab)

MoonLake Immunotherapeutics filed an 8-K covering another company event.
SCHEDULE 13G/A · 14 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in MoonLake Immunotherapeutics.
SCHEDULE 13G · 14 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in MoonLake Immunotherapeutics.
SCHEDULE 13G/A · 14 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in MoonLake Immunotherapeutics.
S-8 · 10 Aug 2026

MoonLake Immunotherapeutics securities registration filing (opens in a new tab)

MoonLake Immunotherapeutics filed a registration or prospectus document concerning securities.

Insider	Date	Transaction	Shares	Average price	Filing
Reich Kristian Chief Scientific Officer	27 Jul 2026	Open-market sale (S)	−1,100	$20.00	Form 4 (opens in a new tab)
Reich Kristian Chief Scientific Officer	22 Jul 2026	Open-market sale (S)	−2,448	$20.00	Form 4 (opens in a new tab)
Reich Kristian Chief Scientific Officer	21 Jul 2026	Open-market sale (S)	−50,000	$20.02	Form 4 (opens in a new tab)
Reich Kristian Chief Scientific Officer	20 Jul 2026	Open-market sale (S)	−43,700	$20.09	Form 4 (opens in a new tab)
Reich Kristian Chief Scientific Officer	15 Jul 2026	Open-market sale (S)	−16,105	$20.01	Form 4 (opens in a new tab)
Santos da Silva Jorge Director, Chief Executive Officer	10 Jul 2026	Open-market sale (S)	−68,289	$20.02	Form 4 (opens in a new tab)
Santos da Silva Jorge Director, Chief Executive Officer	9 Jul 2026	Open-market sale (S)	−33,936	$20.01	Form 4 (opens in a new tab)
Santos da Silva Jorge Director, Chief Executive Officer	1 Jul 2026	Open-market sale (S)	−47,775	$20.03	Form 4 (opens in a new tab)
Bodenstedt Matthias Chief Financial Officer	22 Jun 2026	Open-market sale (S)	−39,120	$22.04	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Bvf Inc/Il	6/30/2026	16,001,284	0%
Deep Track Capital, Lp	6/30/2026	6,999,025	9.209%
T. Rowe Price Investment Management, Inc.	6/30/2026	4,280,624	New
Janus Henderson Group Ltd.	3/31/2026	3,451,628	64.678%
D. E. Shaw & Co., Inc.	6/30/2026	3,365,507	40.777%
Cormorant Asset Management, Lp	6/30/2026	3,205,433	-28.457%
Jupiter Topco Llc	6/30/2026	3,085,906	New
Logos Global Management Lp	6/30/2026	2,675,000	78.333%
Weiss Asset Management Lp	6/30/2026	2,581,813	51.131%
Citadel Advisors Llc	6/30/2026	1,972,893	49.041%

Previous close: 10.32 USD
Day range: 10.34 – 10.73 USD
52-week range: 8.90 – 23.29 USD
Volume: 1,163,561
Market cap: $906.39M
Average volume: 1,613,845
EPS (diluted, trailing four quarters to 30 Jun 2026): −3.84 USD
Shares outstanding: 85.11M
Beta (5Y monthly): 1.12

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 21 Oct 2026, 20:00 UTC· 10 hours ago

Average volume, P/E and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:24 UTC· 9 minutes ago

EPS: SEC EDGAR filings (opens in a new tab) Checked 20 Oct 2026, 11:12 UTC· 1 day ago 10-Q filed 10 Aug 2026

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for MLTX yet

Financial statements
Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.